Изменения в клинических рекомендациях по лечению меланомы кожи и слизистых оболочек 2023 и 2025 гг.

В статье представлен сравнительный анализ российских клинических рекомендаций по лечению меланомы кожи и слизистых оболочек 2020 и 2023 гг., а также зарубежных рекомендаций NCCN (National Comprehensive Cancer Network, Национальная комплексная онкологическая сеть) и ESMO (European Society for Medical Oncology, Европейское общество медицинской онкологии) 2025 г. Выявленные изменения обоснованы наиболее доказательными данными литературы. Вынесены на обсуждение основные дискутабельные вопросы, касающиеся изменений в терапии меланомы в 2025 г. Затрагивается тема модификации лечения больных меланомой с метастазами в головном мозге. Обсуждаются новые опции терапии пациентов с метастатической и нерезектабельной (IIIC–D стадии) меланомой, а также варианты неоадъювантной и адъювантной терапии меланомы кожи II–III стадии. Рассматриваются различные варианты лечения больных с локальной стадией меланомы. Помимо прочего, рекомендации 2025 г. дополнены вариантами лечения меланомы у детей.
Также освещаются изменения в клинических рекомендациях по лечению меланомы кожи и слизистых оболочек для использования в ежедневной клинической практике.

1. Luke J.J., Rutkowski P., Queirolo P. et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022;399(10336):1718–29. DOI: 10.1016/S0140-6736(22)00562-1

2. Kirkwood J.M., del Vecchio M., Weber J. et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 2023;29(11):2835–43. DOI: 10.1038/s41591-023-02583-2

3. Blank C.U., Rozeman E.A., Fanchi L.F. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24(11):1655–61. DOI: 10.1038/s41591-018-0198-0

4. Rozeman E.A., Menzies A.M., van Akkooi A.C.J. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20(7):948–60. DOI: 10.1016/S1470-2045(19)30151-2

5. Blank C.U., Lucas M.W., Scolyer R.A. et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: the phase 3 NADINA trial. J Clin Oncol 2024;42(suppl 17):LBA2. DOI: 10.1200/JCO.2024.42.17_suppl.LBA2

6. Blank C.U., Reijers I.L.M., Saw R.P.M. et al. Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol 2022;40(suppl_16):9501. DOI: 10.1200/JCO.2022.40.16_suppl.9501

7. Dummer R., Flaherty K.T., Robert C. et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol 2022;40(36):4178–88. DOI: 10.1200/JCO.21.02659

8. Dummer R., Ascierto P.A., Gogas H.J. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol 2018;19(5):603–15. DOI: 10.1016/S1470-2045(18)30142-6

9. Gogas H., Dummer R., Ascierto P.A. et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer 2021;152:116–28. DOI: 10.1016/j.ejca.2021.04.028

10. Lebbe C., Meyer N., Mortier L. et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 Trial. J Clin Oncol 2019;37(11):867–75. DOI: 10.1200/JCO.18.01998

11. Olson D.J., Eroglu Z., Brockstein B. et al. Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J Clin Oncol 2021;39(24):2647–55. DOI: 10.1200/JCO.21.00079

12. Самойленко И.В., Демидов Л.В., Моисеенко В.М. и др. Эффективность и безопасность препарата нурулимаб + пролголимаб с продолжением терапии пролголимабом по сравнению с монотерапией пролголимабом в качестве 1-й линии терапии пациентов с нерезектабельной или метастатической меланомой: финальные результаты фазы II клинического исследования OBERTON. Современная Онкология 2023;25(3):313–24. DOI: 10.26442/18151434.2023.3.202463

13. Demidov L., Samoylenko I., Kharkevich G. et al. Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: phase III OCTAVA trial (abstract). Cancer Res 2025;85(8_Suppl_1):653. DOI: 10.1158/1538-7445.AM2025-653

14. Samoylenko I.V., Kolontareva Yu.M., Kogay E.V. et al. Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study. Front Oncol 2024;14:1395378. DOI: 10.3389/fonc.2024.1395378

15. Gutzmer R., Stroyakovskiy D., Gogaset H. et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395(10240):1835–44. DOI: 10.1016/S0140-6736(20)30934-X

16. Ferrucci P.F., Di Giacomo A.M., Del Vecchio M. et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer 2020;8(2):e001806. DOI: 10.1136/jitc-2020-001806

17. Arance A., de la Cruz-Merino L., Petrella T.M. et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol 2023;41(1):75–85. DOI: 10.1200/JCO.22.00221

18. Robert C., Ribas A., Schachter J. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019;20(9):1239–51. DOI: 10.1016/S1470-2045(19)30388-2

19. Schadendorf D., Hassel J.C., Fluck M. et al. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): a randomized, double-blind phase II trial (IMMUNED). Ann Oncol 2019;30:v903–v904. DOI: 10.1093/annonc/mdz394.064

20. Andtbacka R.H., Kaufman H.L., Collichio F. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33(25):2780–8. DOI: 10.1200/JCO.2014.58.3377

21. Kunte C., Letulé V., Gehl J. et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol 2017;176(6):1475–85. DOI: 10.1111/bjd.15340

22. Tawbi H.A., Hodi F.S., Lipson E.J. et al. Nivolumab (NIVO) plus relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years. J Clin Oncol 2024;42(suppl_16):9524. DOI: 10.1200/JCO.2024.42.16_suppl.9524

23. Ascierto P.A., Dummer R., Gaudy-Marqueste C. et al. Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: results from RELATIVITY-048. J Clin Oncol 2024;42(suppl_16):9504. DOI: 10.1200/JCO.2024.42.16_suppl.9504

24. Rohaan M.W., Borch T.H., van den Berg J.H. et al. Tumorinfiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 2022;387(23):2113–25. DOI: 10.1056/NEJMoa2210233

25. Schoenfeld A.J., Lee S.M., de Spéville B.D. et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov 2024;14(8): 1389–402. DOI: 10.1158/2159-8290.CD-23-1334

26. Robert C., Dutriaux C., Oppong F.B. et al. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN). J Clin Oncol 2024;42(suppl_17):LBA9503. DOI: 10.1200/JCO.2024.42.17_suppl.LBA9503

27. Vogelbaum M.A., Brown P.D., Messersmith H. et al. Treatment for brain metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 2022;40(5):492–516. DOI: 10.1200/JCO.21.02314

28. Hasanov M., Martin B., Hasanov E. et al. The 31-GEP to identify patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system. J Clin Oncol 2024; 42(suppl_16):9530. DOI: 10.1200/JCO.2024.42.16_suppl.9530

29. Le Rhun E., Guckenberger M., Smits M. et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors. Ann Oncol 2021;32(11):1332–47. DOI: 10.1016/j.annonc.2021.07.016

30. Sperduto P.W., Mesko S., Li J. et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 2020;38(32):3773–84. DOI: 10.1200/JCO.20.01255

31. Amaral T., Chatziioannou E., Nuebling A. et al. Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 451 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy. J Clin Oncol 2024;42(suppl_16):9574. DOI: 10.1200/JCO.2024.42.16_suppl.9574

32. Khan M., Zhao Z., Arooj S., Liao G. Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis. BMC Cancer 2021;21(1):167. DOI: 10.1186/s12885-021-07889-3

33. Liew D.N., Kano H., Kondziolka D. et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011;114(3):769–79. DOI: 10.3171/2010.5.JNS1014

34. Geoerger B., Kang H.J., Yalon-Oren M. et al. Pembrolizumab in pediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol 2020;21(1):121–33. DOI: 10.1016/S1470-2045(19)30671-0

35. Geoerger B., Bergeron C., Gore L. et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 2017;86:358–63. DOI: 10.1016/j.ejca.2017.09.032

36. Merchant M.S., Wright M., Baird K. et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 2016;22(6):1364–70. DOI: 10.1158/1078-0432.CCR-15-0491

37. Weyand A.C., Mody R.J., Rabah R.M., Opipari V.P. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma. Pediatr Blood Cancer 2018;65(1). DOI: 10.1002/pbc.26702

38. Chisholm J.C., Suvada J., Dunkel I.J. et al. BRIM-P: a phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutationpositive melanoma. Pediatr Blood Cancer 2018;65(5):e26947. DOI: 10.1002/pbc.26947

39. Bay S.B., Kebudi R., Zulfikar B. Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency. Melanoma Res 2019;29(1):99–101. DOI: 10.1097/CMR.0000000000000537

40. Bay S.B., Gorgun O., Kebudi R. Children with malignant melanoma: a single center experience from Turkey. Turk Pediatri Ars 2020;55(1):39–45. DOI: 10.14744/TurkPediatriArs.2019.90022

41. Boddie A.W. Jr, Cangir A. Adjuvant and neoadjuvant chemotherapy with dacarbazine in high-risk childhood melanoma. Cancer 1987;60(8):1720–3. DOI: 10.1002/1097-0142(19871015)60:8<1720::aidcncr2820600805>3.0.co;2-h

42. Wada H., Nemoto K., Ogawa Y. et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 2004;59(2):495–500. DOI: 10.1016/j.ijrobp.2003.11.013

43. Samstein R.M., Carvajal R.D., Postow M.A. et al. Localized sinonasal mucosal melanoma: outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head Neck 2016;38(9):1310–7. DOI: 10.1002/hed.24435

44. Saigal K., Weed D.T., Reis I.M. et al. Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. ISRN Oncol 2012;2012:785131. DOI: 10.5402/2012/785131

45. Plavc G., But-Hadzic J., Anicin A. et al. Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985–2013. Radiat Oncol 2016;11(1):137. DOI: 10.1186/s13014-016-0712-9

46. Krengli M., Masini L., Kaanders J.H. et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006;65(3):751–9. DOI: 10.1016/j.ijrobp.2006.01.016